The commercial market for advanced reactor fuel is small today and growing fast. The HALEU and TRISO segment was valued at USD 0.16 billion in 2026, is estimated at USD 0.21 billion in 2027, and is forecast to reach USD 1.12 billion by 2032 — a compound annual growth rate of 39.77% over 2027–2032.

Supply is still concentrated in one country

Beneath the growth curve sits an uncomfortable supply picture. Russia remains the only established commercial HALEU supplier at scale, while Western capacity is still being developed. The United States, Europe and China are building separate enrichment and fabrication pathways, with early output expected before 2030.

That fragmentation matters for pricing and for contracting. Because the routes are being built in parallel rather than jointly, each region's fuel will need its own qualification chain, and customers will face a menu of suppliers whose output is measured in tens of tonnes rather than hundreds.

The timing mismatch

The central risk in the market is not demand but sequencing. Reactor schedules may advance faster than qualified fuel facilities, creating a gap in which developers have plants under construction and no certified fuel to load.

Developers are likely to place supply agreements earlier, favoring suppliers that can demonstrate regulatory readiness.

That dynamic is already visible in the order book. Urenco has signed three HALEU enrichment agreements with advanced reactor developers — a September 2025 contract linked to Radiant's Kaleidos microreactor, a May 2026 long-term supply agreement with Antares Nuclear, and the November 2026 Blykalla deal — all ahead of first production at its Capenhurst facility, which is scheduled to start operations in 2031.

Demand anchors

The US Department of Energy has projected that US HALEU demand alone could reach 50 metric tons per year by 2035. Set against Urenco's initial Capenhurst capacity of up to 27 tonnes per year, that projection implies Western buyers will be competing for allocation well into the next decade.

For investors, the signal is that value in this market accrues first to whoever can demonstrate licensed, qualified capacity — and that the roughly eightfold expansion forecast by 2032 depends on those facilities hitting their start dates.

This article was assisted by AI analysis. Please refer to the original source for official information.